Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2021

Open Access 01-12-2021 | Breast Cancer | Review

The role of the deubiquitinating enzyme DUB3/USP17 in cancer: a narrative review

Authors: Guang-Fei Yang, Xin Zhang, Yi-Ge Su, Ren Zhao, Yan-Yang Wang

Published in: Cancer Cell International | Issue 1/2021

Login to get access

Abstract

The balance between ubiquitination and deubiquitination is critical for the degradation, transport, localization, and activity of proteins. Deubiquitinating enzymes (DUBs) greatly contribute to the balance of ubiquitination and deubiquitination, and they have been widely studied due to their fundamental role in cancer. DUB3/ubiquitin-specific protease 17 (USP17) is a type of DUB that has attracted much attention in cancer research. In this review, we summarize the biological functions and regulatory mechanisms of USP17 in central nervous system, head and neck, thoracic, breast, gastrointestinal, genitourinary, and gynecologic cancers as well as bone and soft tissue sarcomas, and we provide new insights into how USP17 can be used in the management of cancer.
Literature
1.
Hicke L, Dunn R. Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins. Annu Rev Cell Dev Biol. 2003;19:141–72.PubMedCrossRef
2.
3.
Ciechanover A, Kwon YT. Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies. Exp Mol Med. 2015;47:e147.PubMedPubMedCentralCrossRef
4.
Shi D, Grossman SR. Ubiquitin becomes ubiquitous in cancer: emerging roles of ubiquitin ligases and deubiquitinases in tumorigenesis and as therapeutic targets. Cancer Biol Ther. 2010;10(8):737–47.PubMedPubMedCentralCrossRef
5.
Pickart CM, Eddins MJ. Ubiquitin: structures, functions, mechanisms. Biochim Biophys Acta. 2004;1695(1–3):55–72.PubMedCrossRef
6.
Heideker J, Wertz IE. DUBs, the regulation of cell identity and disease. Biochem J. 2015;467(1):191.PubMedCrossRef
7.
8.
Komander D, Clague MJ, Urbe S. Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol. 2009;10(8):550–63.PubMedCrossRef
9.
10.
Burrows JF, McGrattan MJ, Rascle A, Humbert M, Baek KH, Johnston JA. DUB-3, a cytokine-inducible deubiquitinating enzyme that blocks proliferation. J Biol Chem. 2004;279(14):13993–4000.PubMedCrossRef
11.
Han L, Yang J, Wang X, Wu Q, Yin S, Li Z, et al. The E3 deubiquitinase USP17 is a positive regulator of retinoic acid-related orphan nuclear receptor gammat (RORgammat) in Th17 cells. J Biol Chem. 2014;289(37):25546–55.PubMedPubMedCentralCrossRef
12.
13.
14.
Koegl M, Hoppe T, Schlenker S, Ulrich HD, Mayer TU, Jentsch S. A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell. 1999;96(5):635–44.PubMedCrossRef
15.
16.
Zheng N, Wang P, Jeffrey PD, Pavletich NP. Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases. Cell. 2000;102(4):533–9.PubMedCrossRef
17.
Plechanovova A, Jaffray EG, Tatham MH, Naismith JH, Hay RT. Structure of a RING E3 ligase and ubiquitin-loaded E2 primed for catalysis. Nature. 2012;489(7414):115–20.PubMedPubMedCentralCrossRef
18.
19.
Spratt DE, Walden H, Shaw GS. RBR E3 ubiquitin ligases: new structures, new insights, new questions. Biochem J. 2014;458(3):421–37.PubMedCrossRef
20.
Lechtenberg BC, Rajput A, Sanishvili R, Dobaczewska MK, Ware CF, Mace PD, et al. Structure of a HOIP/E2~ ubiquitin complex reveals RBR E3 ligase mechanism and regulation. Nature. 2016;529(7587):546–50.PubMedPubMedCentralCrossRef
21.
Komander D. The emerging complexity of protein ubiquitination. Biochem Soc Trans. 2009;37(Pt 5):937–53.PubMedCrossRef
22.
Hoeller D, Dikic I. Regulation of ubiquitin receptors by coupled monoubiquitination. Subcell Biochem. 2010;54:31–40.PubMedCrossRef
23.
24.
Amerik AY, Hochstrasser M. Mechanism and function of deubiquitinating enzymes. Biochim Biophys Acta. 2004;1695(1–3):189–207.PubMedCrossRef
25.
Clague MJ, Barsukov I, Coulson JM, Liu H, Rigden DJ, Urbe S. Deubiquitylases from genes to organism. Physiol Rev. 2013;93(3):1289–315.PubMedCrossRef
26.
Reyes-Turcu FE, Ventii KH, Wilkinson KD. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem. 2009;78:363–97.PubMedCrossRef
27.
Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK, et al. A genomic and functional inventory of deubiquitinating enzymes. Cell. 2005;123(5):773–86.PubMedCrossRef
28.
Sippl W, Collura V, Colland F. Ubiquitin-specific proteases as cancer drug targets. Future Oncol. 2011;7(5):619–32.PubMedCrossRef
29.
Hussain S, Zhang Y, Galardy PJ. DUBs and cancer: the role of deubiquitinating enzymes as oncogenes, non-oncogenes and tumor suppressors. Cell Cycle. 2009;8(11):1688–97.PubMedCrossRef
30.
Ducker C, Shaw PE. USP17-mediated de-ubiquitination and cancer: clients cluster around the cell cycle. Int J Biochem Cell Biol. 2021;130:105886.PubMedCrossRef
31.
Burrows JF, Scott CJ, Johnston JA. The DUB/USP17 deubiquitinating enzymes: a gene family within a tandemly repeated sequence, is also embedded within the copy number variable beta-defensin cluster. BMC Genom. 2010;11:250.CrossRef
32.
Hjortland NM, Mesecar AD. Steady-state kinetic studies reveal that the anti-cancer target ubiquitin-specific protease 17 (USP17) is a highly efficient deubiquitinating enzyme. Arch Biochem Biophys. 2016;612:35–45.PubMedPubMedCentralCrossRef
33.
Shin JM, Yoo KJ, Kim MS, Kim D, Baek KH. Hyaluronan- and RNA-binding deubiquitinating enzymes of USP17 family members associated with cell viability. BMC Genom. 2006;7:292.CrossRef
34.
Zeng T, Cui D, Gao L. Glioma: an overview of current classifications, characteristics, molecular biology and target therapies. Front Biosci. 2015;20:1104–15.CrossRef
35.
Hu M, Chen H, Han C, Lan J, Xu Y, Li C, et al. Expression and functional implications of USP17 in glioma. Neurosci Lett. 2016;616:125–31.PubMedCrossRef
36.
Forte S, Pagliuca A, Maniscalchi ET, Gulino R, Calabrese G, Ricci-Vitiani L, et al. Gene expression analysis of PTEN positive glioblastoma stem cells identifies DUB3 and Wee1 modulation in a cell differentiation model. PLoS ONE. 2013;8(12):e81432.PubMedPubMedCentralCrossRef
37.
Luo F, Zhou Z, Cai J, Du W. DUB3 facilitates growth and inhibits apoptosis through enhancing expression of EZH2 in oral squamous cell carcinoma. Onco Targets Ther. 2020;13:1447–60.PubMedPubMedCentralCrossRef
38.
Feng L, Zhang J, Sun M, Qiu F, Chen W, Qiu W. Tumor suppressor LINC02487 inhibits oral squamous cell carcinoma cell migration and invasion through the USP17-SNAI1 axis. Front Oncol. 2020;10:559808.PubMedPubMedCentralCrossRef
39.
McFarlane C, McFarlane S, Paul I, Arthur K, Scheaff M, Kerr K, et al. The deubiquitinating enzyme USP17 is associated with non-small cell lung cancer (NSCLC) recurrence and metastasis. Oncotarget. 2013;4(10):1836–43.PubMedPubMedCentralCrossRef
40.
Darling S, Fielding AB, Sabat-Pospiech D, Prior IA, Coulson JM. Regulation of the cell cycle and centrosome biology by deubiquitylases. Biochem Soc Trans. 2017;45(5):1125–36.PubMedPubMedCentralCrossRef
41.
Hu B, Deng T, Ma H, Liu Y, Feng P, Wei D, et al. Deubiquitinase DUB3 regulates cell cycle progression via stabilizing cyclin A for proliferation of non-small cell lung cancer cells. Cells. 2019;8(4):297.PubMedCentralCrossRef
42.
Jaworski J, de la Vega M, Fletcher SJ, McFarlane C, Greene MK, Smyth AW, et al. USP17 is required for clathrin mediated endocytosis of epidermal growth factor receptor. Oncotarget. 2014;5(16):6964–75.PubMedPubMedCentralCrossRef
43.
McCann AP, Smyth P, Cogo F, McDaid WJ, Jiang L, Lin J, et al. USP17 is required for trafficking and oncogenic signaling of mutant EGFR in NSCLC cells. Cell Commun Signal. 2018;16(1):77.PubMedPubMedCentralCrossRef
44.
Conway EM, Pikor LA, Kung SH, Hamilton MJ, Lam S, Lam WL, et al. Macrophages, inflammation, and lung cancer. Am J Respir Crit Care Med. 2016;193(2):116–30.PubMedCrossRef
45.
Lu CH, Yeh DW, Lai CY, Liu YL, Huang LR, Lee AY, et al. USP17 mediates macrophage-promoted inflammation and stemness in lung cancer cells by regulating TRAF2/TRAF3 complex formation. Oncogene. 2018;37(49):6327–40.PubMedPubMedCentralCrossRef
46.
Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer. 2004;4(7):528–39.PubMedCrossRef
47.
Mehic M, de Sa VK, Hebestreit S, Heldin CH, Heldin P. The deubiquitinating enzymes USP4 and USP17 target hyaluronan synthase 2 and differentially affect its function. Oncogenesis. 2017;6(6):e348.PubMedPubMedCentralCrossRef
48.
Zhang S, Yuan J, Zheng R. Suppression of ubiquitin-specific peptidase 17 (USP17) inhibits tumorigenesis and invasion in non-small cell lung cancer cells. Oncol Res. 2016;24(4):263–9.PubMedPubMedCentralCrossRef
49.
Zhang S, Xu Z, Yuan J, Chen H. Ubiquitin-specific peptidase 17 promotes cisplatin resistance via PI3K/AKT activation in non-small cell lung cancer. Oncol Lett. 2020;20(1):67–74.PubMedPubMedCentralCrossRef
50.
Lin Y, Qiu Y, Xu C, Liu Q, Peng B, Kaufmann GF, et al. Functional role of asparaginyl endopeptidase ubiquitination by TRAF6 in tumor invasion and metastasis. J Natl Cancer Inst. 2014;106(4):dju012.PubMedCrossRef
51.
Chen X, Wang C, Liao K, Zhou S, Cao L, Chen J, et al. USP17 suppresses tumorigenesis and tumor growth through deubiquitinating AEP. Int J Biol Sci. 2019;15(4):738–48.PubMedPubMedCentralCrossRef
52.
Couture JF, Collazo E, Brunzelle JS, Trievel RC. Structural and functional analysis of SET8, a histone H4 Lys-20 methyltransferase. Genes Dev. 2005;19(12):1455–65.PubMedPubMedCentralCrossRef
53.
Fukuura K, Inoue Y, Miyajima C, Watanabe S, Tokugawa M, Morishita D, et al. The ubiquitin-specific protease USP17 prevents cellular senescence by stabilizing the methyltransferase SET8 and transcriptionally repressing p21. J Biol Chem. 2019;294(44):16429–39.PubMedPubMedCentralCrossRef
54.
Liu T, Yu J, Deng M, Yin Y, Zhang H, Luo K, et al. CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1. Nat Commun. 2017;8:13923.PubMedPubMedCentralCrossRef
55.
Wu Y, Wang Y, Lin Y, Liu Y, Wang Y, Jia J, et al. Dub3 inhibition suppresses breast cancer invasion and metastasis by promoting Snail1 degradation. Nat Commun. 2017;8:14228.PubMedPubMedCentralCrossRef
56.
Lin Y, Wang Y, Shi Q, Yu Q, Liu C, Feng J, et al. Stabilization of the transcription factors slug and twist by the deubiquitinase dub3 is a key requirement for tumor metastasis. Oncotarget. 2017;8(43):75127–40.PubMedPubMedCentralCrossRef
57.
58.
Pereg Y, Liu BY, O’Rourke KM, Sagolla M, Dey A, Komuves L, et al. Ubiquitin hydrolase Dub3 promotes oncogenic transformation by stabilizing Cdc25A. Nat Cell Biol. 2010;12(4):400–6.PubMedCrossRef
59.
McFarlane C, Kelvin AA, de la Vega M, Govender U, Scott CJ, Burrows JF, et al. The deubiquitinating enzyme USP17 is highly expressed in tumor biopsies, is cell cycle regulated, and is required for G1-S progression. Cancer Res. 2010;70(8):3329–39.PubMedCrossRef
60.
McGarry TJ, Kirschner MW. Geminin, an inhibitor of DNA replication, is degraded during mitosis. Cell. 1998;93(6):1043–53.PubMedCrossRef
61.
Hernandez-Perez S, Cabrera E, Salido E, Lim M, Reid L, Lakhani SR, et al. DUB3 and USP7 de-ubiquitinating enzymes control replication inhibitor Geminin: molecular characterization and associations with breast cancer. Oncogene. 2017;36(33):4802–9.PubMedCrossRef
62.
Borbely G, Haldosen LA, Dahlman-Wright K, Zhao C. Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cells. Oncotarget. 2015;6(32):33623–35.PubMedPubMedCentralCrossRef
63.
Brinker AM, Ma J, Lipsky PE, Raskin I. Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae). Phytochemistry. 2007;68(6):732–66.PubMedCrossRef
64.
Cheng S, Zhang Z, Hu C, Xing N, Xia Y, Pang B. Pristimerin suppressed breast cancer progression via miR-542–5p/DUB3 axis. Onco Targets Ther. 2020;13:6651–60.PubMedPubMedCentralCrossRef
65.
Zhang P, Sun Y, Ma L. ZEB1: at the crossroads of epithelial–mesenchymal transition, metastasis and therapy resistance. Cell Cycle. 2015;14(4):481–7.PubMedPubMedCentralCrossRef
66.
Wang M, He SF, Liu LL, Sun XX, Yang F, Ge Q, et al. Potential role of ZEB1 as a DNA repair regulator in colorectal cancer cells revealed by cancer-associated promoter profiling. Oncol Rep. 2017;38(4):1941–8.PubMedPubMedCentralCrossRef
67.
Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998;273(10):5858–68.PubMedCrossRef
68.
Delgado-Diaz MR, Martin Y, Berg A, Freire R, Smits VA. Dub3 controls DNA damage signalling by direct deubiquitination of H2AX. Mol Oncol. 2014;8(5):884–93.PubMedPubMedCentralCrossRef
69.
Kim J, D’Annibale S, Magliozzi R, Low TY, Jansen P, Shaltiel IA, et al. USP17- and SCFbetaTrCP-regulated degradation of DEC1 controls the DNA damage response. Mol Cell Biol. 2014;34(22):4177–85.PubMedPubMedCentralCrossRef
70.
Zhang Q, Zhang ZY, Du H, Li SZ, Tu R, Jia YF, et al. DUB3 deubiquitinates and stabilizes NRF2 in chemotherapy resistance of colorectal cancer. Cell Death Differ. 2019;26(11):2300–13.PubMedPubMedCentralCrossRef
71.
Gundem G, Van Loo P, Kremeyer B, Alexandrov LB, Tubio JMC, Papaemmanuil E, et al. The evolutionary history of lethal metastatic prostate cancer. Nature. 2015;520(7547):353–7.PubMedPubMedCentralCrossRef
72.
Baohai X, Shi F, Yongqi F. Inhibition of ubiquitin specific protease 17 restrains prostate cancer proliferation by regulation of epithelial-to-mesenchymal transition (EMT) via ROS production. Biomed Pharmacother. 2019;118:108946.PubMedCrossRef
73.
Jin X, Yan Y, Wang D, Ding D, Ma T, Ye Z, et al. DUB3 promotes BET inhibitor resistance and cancer progression by deubiquitinating BRD4. Mol Cell. 2018;71(4):592-605.e594.PubMedPubMedCentralCrossRef
74.
Ramakrishna S, Suresh B, Lee EJ, Lee HJ, Ahn WS, Baek KH. Lys-63-specific deubiquitination of SDS3 by USP17 regulates HDAC activity. J Biol Chem. 2011;286(12):10505–14.PubMedPubMedCentralCrossRef
75.
Ramakrishna S, Suresh B, Bae SM, Ahn WS, Lim KH, Baek KH. Hyaluronan binding motifs of USP17 and SDS3 exhibit anti-tumor activity. PLoS ONE. 2012;7(5):e37772.PubMedPubMedCentralCrossRef
76.
Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer. 2001;1(3):222–31.PubMedCrossRef
77.
de la Vega M, Burrows JF, McFarlane C, Govender U, Scott CJ, Johnston JA. The deubiquitinating enzyme USP17 blocks N-Ras membrane trafficking and activation but leaves K-Ras unaffected. J Biol Chem. 2010;285(16):12028–36.PubMedPubMedCentralCrossRef
78.
Burrows JF, Kelvin AA, McFarlane C, Burden RE, McGrattan MJ, De la Vega M, et al. USP17 regulates Ras activation and cell proliferation by blocking RCE1 activity. J Biol Chem. 2009;284(14):9587–95.PubMedPubMedCentralCrossRef
79.
Boros J, Donaldson IJ, O’Donnell A, Odrowaz ZA, Zeef L, Lupien M, et al. Elucidation of the ELK1 target gene network reveals a role in the coordinate regulation of core components of the gene regulation machinery. Genome Res. 2009;19(11):1963–73.PubMedPubMedCentralCrossRef
80.
Ducker C, Chow LKY, Saxton J, Handwerger J, McGregor A, Strahl T, et al. De-ubiquitination of ELK-1 by USP17 potentiates mitogenic gene expression and cell proliferation. Nucleic Acids Res. 2019;47(9):4495–508.PubMedPubMedCentralCrossRef
81.
de la Vega M, Kelvin AA, Dunican DJ, McFarlane C, Burrows JF, Jaworski J, et al. The deubiquitinating enzyme USP17 is essential for GTPase subcellular localization and cell motility. Nat Commun. 2011;2:259.PubMedCrossRef
82.
Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, et al. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009;114(1):26–31.PubMedCrossRef
83.
Zhou B, Shu B, Xi T, Su N, Liu J. Dub3 expression correlates with tumor progression and poor prognosis in human epithelial ovarian cancer. Biomed Pharmacother. 2015;70:84–9.PubMedCrossRef
84.
85.
Wu X, Luo Q, Zhao P, Chang W, Wang Y, Shu T, et al. MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer. Proc Natl Acad Sci USA. 2019;116(8):2961–6.PubMedPubMedCentralCrossRef
86.
Song C, Liu W, Li J. USP17 is upregulated in osteosarcoma and promotes cell proliferation, metastasis, and epithelial–mesenchymal transition through stabilizing SMAD4. Tumour Biol. 2017;39(7):1010428317717138.PubMed
87.
Ni Y, Tao L, Chen C, Song H, Li Z, Gao Y, et al. The deubiquitinase USP17 regulates the stability and nuclear function of IL-33. Int J Mol Sci. 2015;16(11):27956–66.PubMedPubMedCentralCrossRef
Metadata
Title
The role of the deubiquitinating enzyme DUB3/USP17 in cancer: a narrative review
Authors
Guang-Fei Yang
Xin Zhang
Yi-Ge Su
Ren Zhao
Yan-Yang Wang
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2021
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-021-02160-y

Other articles of this Issue 1/2021

Cancer Cell International 1/2021 Go to the issue

Review

LINC00261: a burgeoning long noncoding RNA related to cancer

Review

Chemoprotective and chemosensitizing effects of apigenin on cancer therapy

Primary research

Identification of glycolysis related pathways in pancreatic adenocarcinoma and liver hepatocellular carcinoma based on TCGA and GEO datasets

Primary research

RHBDF2 gene functions are correlated to facilitated renal clear cell carcinoma progression

Primary research

Targeting Lymphotoxin Beta and Paired Box 5: a potential therapeutic strategy for soft tissue sarcoma metastasis

Primary research

Prognostic biomarker SMARCC1 and its association with immune infiltrates in hepatocellular carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits